HEALIUS LIMITED (HLS)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

HLS - HEALIUS LIMITED

FNArena Sector : Healthcare services
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: 2.39
Index: ASX200 | ASX300 | ALL-ORDS

Healius, formerly Primary Health Care, is an Australian provider of Pathology, Diagnostic and Day Hospital services. It has been listed since 1998.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$3.03

23 Mar
2023

0.030

OPEN

$3.00

1.00%

HIGH

$3.07

3,946,579

LOW

$3.00

TARGET
$3.128 3.2% upside
Franking for last dividend paid out: 100%
OTHER COMPANIES IN THE SAME SECTOR
EBO . SLA . CAJ . GXL . HSO . MPL . MVF . NHF . RHC . SHL . VRT . MDR . M7T . HLA . PSQ . SIL . PKS . ONT . DOC . BMT . NVL . AHX . ALC . ACL .
FNARENA'S MARKET CONSENSUS FORECASTS
HLS: 1
Title FY21
Actual		 FY22
Actual		 FY23
Forecast		 FY24
Forecast
EPS (cps) xxx 49.9 5.8 xxx
DPS (cps) xxx 16.0 1.7 xxx
EPS Growth xxx 100.0% - 88.3% xxx
DPS Growth xxx 20.8% - 89.2% xxx
PE Ratio xxx N/A 50.0 xxx
Dividend Yield xxx N/A 0.6% xxx
Div Pay Ratio(%) xxx 32.0% 29.6% xxx

Dividend yield today if purchased 3 years ago: 7.11%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 5.50

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 07/09 - ex-div 6c (franking 100%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2023 FactSet UK Limited. All rights reserved
Title 201720182019202020212022
EPS Basic xxxxxxxxxxxxxxx49.9
DPS All xxxxxxxxxxxxxxx16.0
Sales/Revenue xxxxxxxxxxxxxxx2,336.2 M
Book Value Per Share xxxxxxxxxxxxxxx337.6
Net Operating Cash Flow xxxxxxxxxxxxxxx573.8 M
Net Profit Margin xxxxxxxxxxxxxxx12.58 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201720182019202020212022
Return on Capital Employed xxxxxxxxxxxxxxx15.56 %
Return on Invested Capital xxxxxxxxxxxxxxx8.98 %
Return on Assets xxxxxxxxxxxxxxx7.43 %
Return on Equity xxxxxxxxxxxxxxx15.56 %
Return on Total Capital xxxxxxxxxxxxxxx13.37 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx394.3 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201720182019202020212022
Short-Term Debt xxxxxxxxxxxxxxx224 M
Long Term Debt xxxxxxxxxxxxxxx1,555 M
Total Debt xxxxxxxxxxxxxxx1,779 M
Goodwill - Gross xxxxxxxxxxxxxxx2,344 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx81 M
Price To Book Value xxxxxxxxxxxxxxx1.09

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201720182019202020212022
Capex xxxxxxxxxxxxxxx93.5 M
Capex % of Sales xxxxxxxxxxxxxxx4.00 %
Cost of Goods Sold xxxxxxxxxxxxxxx1,547 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx322 M
Research & Development xxxxxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxxxxx6 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

-0.1

No. Of Recommendations

6
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Morgan Stanley

xx/xx/xxxx

5

xxxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Ord Minnett

xx/xx/xxxx

2

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgans

xx/xx/xxxx

3

xxxxxxxxx xx xxxx xxxx xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Macquarie

21/03/2023

1

Outperform

$4.00

32.01%

Australian Clinical Labs ((ACL)) has targeted Healius in an off-market bid at a 4.2% discount to the March 17 closing price, and Macquarie suspects this could rise if Healius meets internal margin targets.

Under the deal, Healius shareholders get 0.74 ACL shares for each Healius share resulting in the latter getting 68% of the merged company, and ACL shareholders emerging with 32%.

Australian Clinical Labs predicts the merger would result in a pre-tax costs synergies of $95m ($55m in the first two years).

Macquarie's calculates Healius's valuation of $4.87 to be well above the offer, and that the offer (at roughly $3.66) is 32% above the share price, suggesting strong upside for Healius shareholders in the merged company if margins are achieved, says the broker.

Outperform rating and $4 target price retained. 

FORECAST
Macquarie forecasts a full year FY23 dividend of 3.00 cents and EPS of 7.50 cents.
Macquarie forecasts a full year FY24 dividend of 12.00 cents and EPS of 19.00 cents.

Citi

xx/xx/xxxx

3

xxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Credit Suisse

xx/xx/xxxx

5

xxxxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Stockbroker Research History >

HLS STOCK CHART

FNArena News on HLS

1
Australian Broker Call *Extra* Edition – Mar 24, 2023

12:31 PM - Daily Market Reports
2
Rudi’s Comprehensive February 2023 Review

Mar 23 2023 - Feature Stories
3
Rudi’s View: All-Weather Stocks – Back In Fashion

Mar 22 2023 - Rudi's View
4
No Enthusiasm To Combine ACL & Healius

Mar 21 2023 - Australia
5
Rudi’s View: Fear & Greed (Rinse & Repeat)

Mar 15 2023 - Rudi's View

Latest Healthcare services News

1
No Enthusiasm To Combine ACL & Healius

Mar 21 2023 - Australia
2
Dr Boreham’s Crucible: Alcidion

Dec 13 2022 - Small Caps
3
No Straight Covid-Relief For Ramsay Health Care

Nov 15 2022 - Australia
4
Dr Boreham’s Crucible: Mach7 Technologies

Nov 14 2022 - Small Caps
5
Negative Industry Trends Impact Australian Clinical Labs

Aug 12 2022 - Small Caps
6
Healius Offers Digital Carrot, Base Remains Soft

May 25 2022 - Australia
7
Ramsay Stakes Future on Mental Health

Dec 20 2021 - Australia
8
Ramsay Health Care: Finally A Break-Out

Nov 09 2021 - Technicals
9
Funding Overhang Weighs On Ramsay’s Rebound

Jun 10 2021 - Australia
10
Treasure Chest: More Pfizer Growth For Ebos Group

May 24 2021 - Treasure Chest